Companies Cryptocurrencies
Urovant Sciences Ltd
Urovant Sciences Ltd
Exchange: NasdaqGS
IPO Date: 27/09/2018
CEO: Mr. Keith Katkin
Biotechnology Healthcare 🔗
  • UROV
  • price
  • market cap
  • changes
If you bought

shares of Urovant Sciences Ltd (UROV) on
You would have made
Old Price $12 Current Price $12

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. The company is headquartered in Irvine, California and currently employs 39 full-time employees. The firm is focused on developing and commercializing therapies for urologic conditions. Its product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist. is focused on evaluating vibegron in its over 1,400 patients, pivotal phase-3 clinical trial for the treatment of overactive bladder (OAB). The Company’s subsidiaries include Urovant Sciences, Inc., Urovant Holdings Limited, and Urovant Sciences GmbH.

Address: 5281 California Ave Ste 100 Irvine CALIFORNIA

Stay updated.